Positive modulator of small- and intermediate- conductance Ca2+-activated K+ channels (KCa2 and KCa3.1 channels); increases Ca2+ sensitivity. Displays no activity at BK channels.
|Storage||Store at +4°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 231.04. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||4.33 mL||21.64 mL||43.28 mL|
|5 mM||0.87 mL||4.33 mL||8.66 mL|
|10 mM||0.43 mL||2.16 mL||4.33 mL|
|50 mM||0.09 mL||0.43 mL||0.87 mL|
References are publications that support the biological activity of the product.
Grgic et al (2009) Endothelial Ca2+-activated K+ channels in normal and impaired EDHF-dilator responses - relevance to cardiovascular pathologies and drug discovery. Br.J.Pharmacol. 157 509 PMID: 19302590
Strobaek et al (2004) Activation of human IK and SK Ca2+-activated K+ channels by NS309 (6,7-dichloro-1H-indole-2,3-dione 3-oxime). Biochim.Biophys.Acta 1665 1 PMID: 15471565
Morimura et al (2006) Voltage-dependent Ca2+-channel block by openers of intermediate and small conductance Ca2+-activated K+ channels in urinary bladder smooth muscle cells. J.Pharm.Sci. 100 237
If you know of a relevant reference for NS 309, please let us know.
View Related Products by Product Action
Keywords: NS 309, NS 309 supplier, NS309, Ca2+-activated, potassium, K+, KCa, channels, activators, positive, modulators, small, intermediate, conductance, SK, IK, KCa2, KCa3, Ca2+-Activated, Potassium, Channels, 3895, Tocris Bioscience
5 Citations for NS 309
Citations are publications that use Tocris products. Selected citations for NS 309 include:
Wong et al (2014) Sex differences in endothelial function in porcine coronary arteries: a role for H2O2 and gap junctions?. Br J Pharmacol 171 2751 PMID: 24467384
Oliveira et al (2010) Altered expression and function of small-conductance (SK) Ca(2+)-activated K+ channels in pilocarpine-treated epileptic rats. Brain Res 1348 187 PMID: 20553876
Hipólito et al (2015) In vivo activation of the SK channel in the spinal cord reduces the NMDA receptor antagonist dose needed to produce antinociception in an inflammatory pain model. Pain 156 849 PMID: 25734988
D'Alessandro et al (2013) KCa3.1 channels are involved in the infiltrative behavior of glioblastoma in vivo. Cell Death Dis 4 e773 PMID: 23949222
Zhang et al (2015) Molecular overlap in the regulation of SK channels by small molecules and phosphoinositides. Neurochem Int 1 e1500008 PMID: 26366439
Do you know of a great paper that uses NS 309 from Tocris? Please let us know.
Reviews for NS 309
Average Rating: 5 (Based on 1 Review.)
Have you used NS 309?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
NS 309 is a potent Kca channel activator. I worked with 10,20,30,40,50,80,100 micrograms dissolved in DMSO. The product worked nicely in experimental conditions and would suggest to others researching Kca channel activation.
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.